Full Press Release Details
Champions Biotechnology, Inc.
855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA.
Champions Biotechnology Awarded $1.46 million in Grants
Baltimore, MD, November 2, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in
the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today
received $1.46 million in grants as part of the Qualifying Therapeutic Discovery Project ( QTDP ). The QTDP was enacted
as part of the Patient Protection and Affordable Care Act of 2010.
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor
specific data to enhance and accelerate the value of oncology drugs. The Company s Preclinical Platform is a novel
approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the
resulting xenografts (Biomerk Tumorgrafts ) in a manner that preserves the biological characteristics of the original
human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to
drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates. The Company also offers its predictive preclinical platform and tumor specific data to
physicians for personalized patient care and to Companies for evaluation of oncology drugs and drug candidates in
models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation
of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.
This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Act
of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as
believe, may, could, will, intend, expect, anticipate, plan, and similar expressions to identify
forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company s
actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen
factors. See Champions Biotechnology s Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such
risks, uncertainties and other factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made,
and Champions Biotechnology s future results, levels of activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in Champions Biotechnology s expectations, except
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com